Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Evolus, Inc. stock logo
EOLS
Evolus
$9.21
+0.1%
$10.07
$8.67
$17.82
$593.17M0.97753,701 shs1.07 million shs
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
$51.13
-3.5%
$48.82
$1.16
$14.10
$2.22B-0.12189,291 shs285,856 shs
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$2.64
+2.7%
$2.68
$1.83
$7.48
$2.27B0.086.15 million shs6.75 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$37.68
+2.5%
$33.57
$27.12
$60.90
$2.20B2.41964,321 shs1.16 million shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Evolus, Inc. stock logo
EOLS
Evolus
+0.11%+1.21%-7.62%-19.14%-13.60%
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
-3.46%-7.04%+9.53%+5.36%+10.03%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
+2.72%-4.35%-1.12%-11.11%-57.28%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
+2.53%+1.87%+21.27%+0.48%-20.37%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Evolus, Inc. stock logo
EOLS
Evolus
4.0693 of 5 stars
3.50.00.03.53.33.30.6
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
2.0518 of 5 stars
3.61.00.00.01.81.70.6
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
4.4938 of 5 stars
4.42.00.04.43.00.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Evolus, Inc. stock logo
EOLS
Evolus
3.00
Buy$23.75157.87% Upside
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
0.00
N/AN/AN/A
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
3.20
Buy$12.25364.02% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.70
Moderate Buy$50.4033.76% Upside

Current Analyst Ratings Breakdown

Latest EOLS, GMTX, IBRX, and TWST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/4/2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
6/3/2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00
5/28/2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00
5/20/2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Overweight$4.25 ➝ $5.00
5/12/2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
5/12/2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00
5/8/2025
Evolus, Inc. stock logo
EOLS
Evolus
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$55.00 ➝ $48.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$54.00 ➝ $44.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$40.00 ➝ $33.00
(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Evolus, Inc. stock logo
EOLS
Evolus
$266.27M2.23N/AN/A$0.09 per share102.33
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/AN/AN/AN/A$2.89 per shareN/A
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$14.74M158.08N/AN/A($0.57) per share-4.63
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$312.97M7.21N/AN/A$8.07 per share4.67
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Evolus, Inc. stock logo
EOLS
Evolus
-$50.42M-$0.89N/AN/AN/A-20.40%-759.04%-20.14%7/30/2025 (Estimated)
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/A
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$413.56M-$0.58N/AN/AN/A-1,310.30%N/A-121.88%8/11/2025 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$208.73M-$3.25N/AN/AN/A-54.98%-33.48%-25.34%8/1/2025 (Estimated)

Latest EOLS, GMTX, IBRX, and TWST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
Evolus, Inc. stock logo
EOLS
Evolus
-$0.09N/AN/AN/A$82.18 millionN/A
5/12/2025Q1 2025
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$0.12-$0.15-$0.03-$0.15$17.50 million$16.52 million
5/5/2025Q2 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.56-$0.66-$0.10-$0.66$92.00 million$92.79 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Evolus, Inc. stock logo
EOLS
Evolus
N/AN/AN/AN/AN/A
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/AN/AN/AN/AN/A
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Evolus, Inc. stock logo
EOLS
Evolus
22.00
2.34
2.16
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
N/A
71.49
71.49
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/A
2.22
2.05
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
4.51
4.24

Institutional Ownership

CompanyInstitutional Ownership
Evolus, Inc. stock logo
EOLS
Evolus
90.69%
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
75.42%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
8.58%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
Evolus, Inc. stock logo
EOLS
Evolus
5.90%
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
12.90%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
76.79%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Evolus, Inc. stock logo
EOLS
Evolus
17064.48 million60.67 millionOptionable
Gemini Therapeutics, Inc. stock logo
GMTX
Gemini Therapeutics
3043.33 million37.74 millionNot Optionable
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
590882.62 million204.86 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99059.92 million58.11 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Evolus stock logo

Evolus NASDAQ:EOLS

$9.21 +0.01 (+0.11%)
Closing price 07/2/2025 04:00 PM Eastern
Extended Trading
$9.18 -0.03 (-0.37%)
As of 07/2/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Gemini Therapeutics stock logo

Gemini Therapeutics NASDAQ:GMTX

$51.13 -1.83 (-3.46%)
As of 07/1/2025

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

ImmunityBio stock logo

ImmunityBio NASDAQ:IBRX

$2.64 +0.07 (+2.72%)
Closing price 07/2/2025 04:00 PM Eastern
Extended Trading
$2.67 +0.03 (+1.29%)
As of 07/2/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$37.68 +0.93 (+2.53%)
Closing price 07/2/2025 04:00 PM Eastern
Extended Trading
$37.68 +0.01 (+0.01%)
As of 07/2/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.